Adam M. Weidner

Array ( [id] => 19112859 [patent_doc_number] => 20240124609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => HUMAN MONOCLONAL ANTIBODIES TO GANGLIOSIDE GD2 [patent_app_type] => utility [patent_app_number] => 18/363136 [patent_app_country] => US [patent_app_date] => 2023-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28217 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18363136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20180512 [patent_doc_number] => 20250264470 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-21 [patent_title] => DIAGNOSIS, PROGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS [patent_app_type] => utility [patent_app_number] => 18/998119 [patent_app_country] => US [patent_app_date] => 2023-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14220 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18998119 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19157751 [patent_doc_number] => 20240150458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => ANTI-LRP5/6 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/350589 [patent_app_country] => US [patent_app_date] => 2023-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34999 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18350589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861915 [patent_doc_number] => 20230416350 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => TAU-BINDING ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/344945 [patent_app_country] => US [patent_app_date] => 2023-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25804 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18344945 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 21010813 [patent_doc_number] => 12747288 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-09-29 [patent_title] => Tau-binding antibodies [patent_app_type] => utility [patent_app_number] => 18/344930 [patent_app_country] => US [patent_app_date] => 2023-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 21216 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18344930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20770209 [patent_doc_number] => 12653861 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-16 [patent_title] => Methods and compositions for treating Huntington's Disease [patent_app_type] => utility [patent_app_number] => 18/344757 [patent_app_country] => US [patent_app_date] => 2023-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 41 [patent_no_of_words] => 23189 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18344757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18693021 [patent_doc_number] => 20230323402 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => Targeted Gene Therapies for Pain and Other Neuro-Related Disorders [patent_app_type] => utility [patent_app_number] => 18/331607 [patent_app_country] => US [patent_app_date] => 2023-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12811 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18331607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18725866 [patent_doc_number] => 20230340095 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => TREATMENT OF TAUOPATHIES [patent_app_type] => utility [patent_app_number] => 18/314956 [patent_app_country] => US [patent_app_date] => 2023-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38386 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18314956 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19020191 [patent_doc_number] => 20240076362 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => ANTI-MS4A4A ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/310207 [patent_app_country] => US [patent_app_date] => 2023-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 76305 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18310207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18754014 [patent_doc_number] => 20230357378 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT OF NEUROPATHIC PAIN [patent_app_type] => utility [patent_app_number] => 18/301803 [patent_app_country] => US [patent_app_date] => 2023-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34636 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 1 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18301803 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18596082 [patent_doc_number] => 20230270873 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES [patent_app_type] => utility [patent_app_number] => 18/181623 [patent_app_country] => US [patent_app_date] => 2023-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35551 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18181623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19020215 [patent_doc_number] => 20240076386 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => ANTI-E-SELECTIN ANTIBODIES, COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/174974 [patent_app_country] => US [patent_app_date] => 2023-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 75283 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18174974 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18754061 [patent_doc_number] => 20230357433 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => INFLAMMATORY CYTOKINES AND FATIGUE IN SUBJECT WITH A COMPLEMENT MEDIATED DISEASE [patent_app_type] => utility [patent_app_number] => 18/164521 [patent_app_country] => US [patent_app_date] => 2023-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19359 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18164521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19330657 [patent_doc_number] => 20240245087 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => Fermented Camel Milk with Propolis-Engineered Probiotic for Treating Adverse Bowel Disorders [patent_app_type] => utility [patent_app_number] => 18/100626 [patent_app_country] => US [patent_app_date] => 2023-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3713 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18100626 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18497456 [patent_doc_number] => 20230220093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => Multispecific Antibodies, Compositions Comprising the Same, and Vectors and Uses Thereof [patent_app_type] => utility [patent_app_number] => 18/151227 [patent_app_country] => US [patent_app_date] => 2023-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38192 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18151227 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19462482 [patent_doc_number] => 20240316151 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => USE OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2 IN THE PREPARATION OF DRUGS FOR THE TREATMENT OF NEUROLOGICAL DEMYELINATING DISEASES [patent_app_type] => utility [patent_app_number] => 18/579591 [patent_app_country] => US [patent_app_date] => 2022-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2691 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18579591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18733426 [patent_doc_number] => 11802149 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-31 [patent_title] => Anti-amyloid beta antibodies and methods of using the same [patent_app_type] => utility [patent_app_number] => 18/050553 [patent_app_country] => US [patent_app_date] => 2022-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 11233 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18050553 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19631185 [patent_doc_number] => 20240409634 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-12 [patent_title] => CD33 x Vd2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/691254 [patent_app_country] => US [patent_app_date] => 2022-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22234 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18691254 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18108122 [patent_doc_number] => 20230001002 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES [patent_app_type] => utility [patent_app_number] => 17/930522 [patent_app_country] => US [patent_app_date] => 2022-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35557 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19571896 [patent_doc_number] => 20240376188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => MONOCLONAL ANTIBODIES TARGETING ACETYLATED TAU AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/690409 [patent_app_country] => US [patent_app_date] => 2022-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20774 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18690409 [rel_patent_id] =>[rel_patent_doc_number] =>)